Posted by Michael Wonder on 07 May 2017
Institute for Clinical and Economic Review's draft evidence report on abuse-deterrent opioids evaluates clinical and economic evidence on nine formulations
5 May 2017 - Public comment period now open until 2 June; requests to make oral comment during public meeting also being accepted.
The Institute for Clinical and Economic Review (ICER) has released a draft evidence report assessing the comparative clinical effectiveness and value of abuse-deterrent opioids. These formulations contain abuse-deterrent properties, including chemical or physical barriers, aversive agents, or agonist/antagonist combinations, that make it more difficult for those taking the drugs to misuse them.
ICER's report assesses evidence on nine abuse-deterrent formulations of opioid medications to evaluate how effectively these drugs reduce opioid misuse or abuse and the many consequences. Economic analyses provide information on the long-term value of abuse-deterrent opioids based on the benefit they provide. ICER's report and accompanying draft voting questions are now open to public comment for four weeks.
